Inicio › Cáncer de pulmón de células no pequeñas › Maine

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Maine

16 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Maine.

Ciudades en Maine

Texto oficial del estudio (inglés)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

MaineHealth Coastal Cancer Treatment Center, Bath
MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
MaineHealth Maine Medical Center - Portland, Portland
y 3 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07293247

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

New England Cancer Specialists ( Site 0139), Westbrook

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Maine Medical Center- Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

New England Cancer Specialists ( Site 0095), Westbrook

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06312137

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Maine Medical Center, Portland
MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06758401

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

New England Cancer Specialists ( Site 0143), Westbrook

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06170788

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

New England Cancer Specialists, Westbrook

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Scarborough

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06692738

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, South Portland

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07291037

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 may 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

ReclutandoFase 2

18 Minutes · Todos los sexos · Actualizado el 5 may 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
y 5 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
MaineHealth Maine Medical Center - Biddeford, Biddeford
y 7 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 mar 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Scarborough

ReclutandoEstudio observacional

Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.